Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (3031) 3031
Publication (165) 165
Book Review (43) 43
Book Chapter (23) 23
Magazine Article (20) 20
Conference Proceeding (4) 4
Book / eBook (2) 2
Paper (1) 1
Trade Publication Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (2619) 2619
female (1415) 1415
male (1215) 1215
index medicus (1012) 1012
adult (984) 984
angioedema (919) 919
middle aged (890) 890
angioedema - drug therapy (884) 884
allergy (683) 683
angioedema - chemically induced (667) 667
immunology (649) 649
aged (553) 553
hereditary angioedema (536) 536
angioneurotic edema (480) 480
angioedema - diagnosis (401) 401
adolescent (395) 395
angiotensin-converting enzyme inhibitors - adverse effects (390) 390
angioedemas, hereditary - drug therapy (360) 360
angioedema - genetics (339) 339
management (336) 336
treatment outcome (332) 332
angioedema - etiology (325) 325
child (314) 314
medicine, general & internal (299) 299
edema (294) 294
urticaria (289) 289
bradykinin (288) 288
urticaria - drug therapy (285) 285
drug therapy (252) 252
therapy (250) 250
diagnosis (224) 224
diagnosis, differential (224) 224
chronic disease (214) 214
complement c1 inhibitor protein - therapeutic use (211) 211
danazol - therapeutic use (210) 210
risk factors (204) 204
allergy and immunology (202) 202
care and treatment (198) 198
angioedema - therapy (197) 197
dermatology (197) 197
angioedema - immunology (190) 190
pharmacology & pharmacy (187) 187
bradykinin - analogs & derivatives (179) 179
hypertension - drug therapy (179) 179
patients (173) 173
young adult (172) 172
c1 inhibitor (169) 169
animals (158) 158
urticaria - etiology (156) 156
angioedema - complications (154) 154
angiotensin-converting enzyme inhibitors - therapeutic use (148) 148
c1 inhibitor deficiency (147) 147
complement c1 inactivator proteins - therapeutic use (146) 146
retrospective studies (146) 146
deficiency (145) 145
histamine h1 antagonists - therapeutic use (145) 145
internal medicine (143) 143
urticaria - diagnosis (143) 143
bradykinin - therapeutic use (140) 140
complement c1 inactivator proteins - deficiency (140) 140
time factors (136) 136
acute disease (133) 133
aged, 80 and over (131) 131
child, preschool (131) 131
icatibant (131) 131
angioneurotic-edema (129) 129
ace inhibitors (125) 125
angioedema - physiopathology (125) 125
abridged index medicus (122) 122
angioedemas, hereditary - diagnosis (119) 119
anaphylaxis (115) 115
plasma (111) 111
chronic idiopathic urticaria (109) 109
enzymes (108) 108
medicine & public health (108) 108
recurrence (108) 108
allergies (107) 107
research (105) 105
c1-inhibitor (103) 103
complement c1 inhibitor protein (103) 103
urticaria - immunology (102) 102
angiotensin (101) 101
complications and side effects (99) 99
hypersensitivity (99) 99
attacks (98) 98
quality of life (96) 96
asthma (95) 95
efficacy (93) 93
double-blind (92) 92
pediatrics (92) 92
angioedema - pathology (91) 91
health aspects (90) 90
prophylaxis (90) 90
safety (90) 90
complement c1 inhibitor protein - administration & dosage (89) 89
drug hypersensitivity - etiology (89) 89
pregnancy (89) 89
urticaria - chemically induced (89) 89
analysis (86) 86
angioedema - epidemiology (86) 86
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2607) 2607
German (138) 138
French (124) 124
Spanish (66) 66
Japanese (20) 20
Polish (20) 20
Italian (16) 16
Russian (15) 15
Danish (11) 11
Dutch (10) 10
Norwegian (6) 6
Croatian (5) 5
Hungarian (5) 5
Hebrew (4) 4
Korean (4) 4
Romanian (4) 4
Finnish (3) 3
Swedish (3) 3
Chinese (2) 2
Portuguese (2) 2
Serbian (2) 2
Turkish (2) 2
Afrikaans (1) 1
Arabic (1) 1
Bosnian (1) 1
Czech (1) 1
Lithuanian (1) 1
Slovak (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Complement, a target for therapy in inflammatory and degenerative diseases
by Morgan, B. Paul and Harris, Claire L
Nature Reviews Drug Discovery, ISSN 1474-1776, 12/2015, Volume 14, Issue 12, pp. 857 - 877
The complement system is a key innate immune defence against infection and an important driver of inflammation; however, these very properties can also cause... 
HEMOLYTIC-UREMIC SYNDROME | HEREDITARY ANGIOEDEMA ATTACKS | ALTERNATIVE PATHWAY | BIOTECHNOLOGY & APPLIED MICROBIOLOGY | C1 ESTERASE INHIBITOR | ACUTE LUNG INJURY | MACULAR DEGENERATION | PHARMACOLOGY & PHARMACY | COBRA VENOM FACTOR | FACTOR-H | MONOCLONAL-ANTIBODY | PAROXYSMAL-NOCTURNAL HEMOGLOBINURIA | Complement Inactivating Agents - pharmacology | Inflammation - drug therapy | Humans | Complement System Proteins - immunology | Clinical Trials as Topic | Complement Inactivating Agents - immunology | Inflammation - immunology | Complement Activation - immunology | Complement Activation - drug effects | Molecular targeted therapy | Care and treatment | Complement system | Inflammation | Observations | Methods
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Telmisartan, Ramipril, or Both in Patients at High Risk for Vascular Events
by Yusuf, Salim and Teo, Koon K and Pogue, Janice and Dyal, Leanne and Copland, Ingrid and Schumacher, Helmut and Dagenais, Gilles and Sleight, Peter and Anderson, Craig and The ONTARGET Investigators and ONTARGET Investigators and Naturvetenskapliga fakulteten and Faculty of Sciences and Göteborgs universitet and Institutionen för cell- och molekylärbiologi and Gothenburg University and Department of Cell and Molecular Biology and Sahlgrenska Academy and Sahlgrenska akademin and Institutionen för medicin, avdelningen för akut och kardiovaskulär medicin and Institute of Medicine, Department of Emergeny and Cardiovascular Medicine
The New England Journal of Medicine, ISSN 0028-4793, 04/2008, Volume 358, Issue 15, pp. 1547 - 1559
This large trial compared the angiotensin-receptor blocker telmisartan, the angiotensin-converting–enzyme inhibitor ramipril, and combination therapy with both... 
MEDICINE, GENERAL & INTERNAL | DESIGN | LEFT-VENTRICULAR DYSFUNCTION | MYOCARDIAL-INFARCTION | CARDIOVASCULAR EVENTS | DOUBLE-BLIND | SYSTOLIC DYSFUNCTION | RANDOMIZED CLINICAL-TRIALS | CONGESTIVE-HEART-FAILURE | COMBINATION | CONVERTING-ENZYME-INHIBITORS | Benzoates - adverse effects | Angiotensin II Type 1 Receptor Blockers - adverse effects | Benzoates - therapeutic use | Follow-Up Studies | Angiotensin II Type 1 Receptor Blockers - therapeutic use | Cardiovascular Diseases - drug therapy | Humans | Middle Aged | Male | Risk | Angiotensin-Converting Enzyme Inhibitors - therapeutic use | Angiotensin-Converting Enzyme Inhibitors - adverse effects | Cardiovascular Diseases - epidemiology | Cardiovascular Diseases - mortality | Female | Blood Pressure - drug effects | Ramipril - therapeutic use | Benzimidazoles - adverse effects | Drug Therapy, Combination | Ramipril - adverse effects | Benzimidazoles - therapeutic use | Double-Blind Method | Diabetes Mellitus - drug therapy | Kaplan-Meier Estimate | Hospitalization | Creatinine - blood | Angioedema - chemically induced | Aged | Complications and side effects | Ramipril | Drug therapy, Combination | Diabetes | Cardiovascular diseases | Drug therapy | Comparative analysis | Risk factors | Telmisartan | Clinical trials | Vein & artery diseases | Cardiovascular disease | Pharmacology | Clinical outcomes | Index Medicus | Abridged Index Medicus | Blood Pressure | Benzimidazoles | Cardiovascular Diseases | MEDICIN OCH HÄLSOVETENSKAP | Angiotensin II Type 1 Receptor Blockers | epidemiology | Angiotensin-Converting Enzyme Inhibitors | Combination | MEDICAL AND HEALTH SCIENCES | Creatinine | chemically induced | Benzoates | drug therapy | Angioedema | drug effects | Diabetes Mellitus | blood | adverse effects | mortality | therapeutic use | Kaplan-Meiers Estimate
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text 2016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure: An Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America
by Yancy, Clyde W and Jessup, Mariell and Bozkurt, Biykem and Butler, Javed and Casey, Donald E and Colvin, Monica M and Drazner, Mark H and Filippatos, Gerasimos and Fonarow, Gregg C and Givertz, Michael M and Hollenberg, Steven M and Lindenfeld, JoAnn and Masoudi, Frederick A and McBride, Patrick E and Peterson, Pamela N and Stevenson, Lynne Warner and Westlake, Cheryl and WRITING COMMITTEE MEMBERS
Circulation, ISSN 0009-7322, 09/2016, Volume 134, Issue 13, pp. e282 - e293
heart failure | angiotensin-converting enzyme inhibitors | CARDIAC & CARDIOVASCULAR SYSTEMS | angiotensin receptor blockers | MYOCARDIAL-INFARCTION | OF-CARDIOLOGY | beta blockers | NEPRILYSIN INHIBITOR | angiotensin receptor-neprilysin inhibitor | AHA Scientific Statements | RANDOMIZED TRIAL | angioedema | natriuretic peptides | focused update | ivabradine | CONVERTING-ENZYME-INHIBITOR | LEFT-VENTRICULAR DYSFUNCTION | MORBIDITY | HIGH-RISK | DOUBLE-BLIND | PERIPHERAL VASCULAR DISEASE | CORONARY-ARTERY-DISEASE | American Heart Association | Heart Failure - therapy | United States | Humans | Heart Failure - physiopathology | Female | Male | Heart Failure - diagnosis | Advisory Committees | Practice Guidelines as Topic | Heart failure | Practice guidelines (Medicine) | Research | Drug therapy | Analysis
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Classification, diagnosis, and approach to treatment for angioedema: consensus report from the Hereditary Angioedema International Working Group
by Cicardi, M and Aberer, W and Banerji, A and Bas, M and Bernstein, J. A and Bork, K and Caballero, T and Farkas, H and Grumach, A and Kaplan, A. P and Riedl, M. A and Triggiani, M and Zanichelli, A and Zuraw, B and EAACI and HAWK and HAWK under the patronage of EAACI (European Academy of Allergy and Clinical Immunology) and HAWK, under the patronage of EAACI (European Academy of Allergy and Clinical Immunology)
Allergy, ISSN 0105-4538, 05/2014, Volume 69, Issue 5, pp. 602 - 616
Angioedema is defined as localized and self‐limiting edema of the subcutaneous and submucosal tissue, due to a temporary increase in vascular permeability... 
angioedema | dermatology | education | clinical immunology | urticaria | ACUTE ATTACKS | IDIOPATHIC NONHISTAMINERGIC ANGIOEDEMA | ACQUIRED C1-INHIBITOR DEFICIENCY | IMMUNOLOGY | ANGIONEUROTIC-EDEMA | FACTOR-XII | CONVERTING-ENZYME-INHIBITORS | TRANEXAMIC ACID | C1 INHIBITOR DEFICIENCY | ALLERGY | BRADYKININ-MEDIATED ANGIOEDEMA | ESTERASE INHIBITOR | Angioedema - drug therapy | Angioedema - diagnosis | Angioedema - etiology | Humans | Angioneurotic edema | Diagnosis | Permeability | Drug therapy | Analysis | Allergies | Classification
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Therapeutic peptides
by Albericio, Fernando and Kruger, Hendrik G
Future Medicinal Chemistry, ISSN 1756-8919, 08/2012, Volume 4, Issue 12, pp. 1527 - 1531
Lymphoma - drug therapy | Peptides - chemistry | Bacterial Infections - drug therapy | Humans | Drug Design | Drug Approval | Prodrugs - chemistry | Prodrugs - therapeutic use | Angioedemas, Hereditary - drug therapy | Peptides - therapeutic use | RNA Virus Infections - drug therapy
Journal Article
Details down arrow
6. Full Text Angiotensin–Neprilysin Inhibition versus Enalapril in Heart Failure
by McMurray, John J.V and Packer, Milton and Desai, Akshay S and Gong, Jianjian and Lefkowitz, Martin P and Rizkala, Adel R and Rouleau, Jean L and Shi, Victor C and Solomon, Scott D and Swedberg, Karl and Zile, Michael R and PARADIGM-HF Investigators Comm and PARADIGM-HF Investigators and Committees and Sahlgrenska akademin and Institute of Medicine, Department of Molecular and Clinical Medicine and Institutionen för medicin, avdelningen för molekylär och klinisk medicin and Göteborgs universitet and Gothenburg University and Sahlgrenska Academy
The New England Journal of Medicine, ISSN 0028-4793, 09/2014, Volume 371, Issue 11, pp. 993 - 1004
The angiotensin receptor–neprilysin inhibitor LCZ696 was compared with the ACE inhibitor enalapril in patients with advanced heart failure. LCZ696 was superior... 
NEUTRAL ENDOPEPTIDASE INHIBITION | NATRIURETIC-PEPTIDE | MORTALITY | SURVIVAL | MEDICINE, GENERAL & INTERNAL | CONVERTING ENZYME-INHIBITION | MORBIDITY | EJECTION FRACTION | DOUBLE-BLIND | RANDOMIZED-TRIAL | RECEPTOR | Double-Blind Method | Humans | Middle Aged | Kaplan-Meier Estimate | Aminobutyrates - adverse effects | Hospitalization - statistics & numerical data | Male | Aminobutyrates - therapeutic use | Enalapril - therapeutic use | Enalapril - adverse effects | Heart Failure - drug therapy | Stroke Volume | Angiotensin-Converting Enzyme Inhibitors - therapeutic use | Angiotensin-Converting Enzyme Inhibitors - adverse effects | Neprilysin - antagonists & inhibitors | Female | Tetrazoles - therapeutic use | Aged | Tetrazoles - adverse effects | Angiotensin Receptor Antagonists - therapeutic use | Drug Combinations | Angiotensin Receptor Antagonists - adverse effects | Heart Failure - mortality | Heart failure | Enalapril | Patient outcomes | Angiotensin | Enalaprilat | Dosage and administration | Research | Drug therapy | Enzymes | Statistical analysis | Mortality | Angioedema | Hypotension | Cough | Studies | Hyperkalemia | Death | Neprilysin | Heart diseases | Klinisk medicin | Medicine | Clinical Medicine | General & Internal
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights